Opinion

Video

First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy

Paul E. Dato, MD, discusses how treatment selection between triplet therapy, doublet therapy, or androgen deprivation monotherapy should be based on disease volume, risk factors, patient age, fitness for chemotherapy, and patient preferences through shared decision-making.

Clinical Brief: Personalizing Treatment Selection in Metastatic Prostate Cancer

Main Discussion Topics

  • Triplet Therapy Indications: High-volume, high-risk symptomatic disease with visceral metastases
  • Patient Selection for Chemotherapy: Younger, chemotherapy-fit patients with visceral disease and high symptom burden
  • Alternative Approaches: Doublet therapy for chemotherapy-reluctant or unfit patients
  • Shared Decision-Making: Balancing treatment efficacy with patient preferences and quality of life goals

Key Points for Physicians

  • Chemotherapy is particularly beneficial for patients requiring rapid tumor reduction
  • Doublet therapy preferred for low-volume/low-risk disease or patients without adverse molecular markers
  • Androgen deprivation monotherapy may be appropriate for elderly patients with high frailty scores or significant comorbidities
  • Patient education about treatment rationale is essential for informed consent and decision-making

Notable Insights

The presenter acknowledges that chemotherapy is not an easy treatment to endure and emphasizes the importance of helping patients understand the clinical rationale and benefits to make the best personal decision.

Clinical Significance

Treatment selection in metastatic prostate cancer requires balancing objective disease characteristics with patient-specific factors through shared decision-making to optimize both clinical outcomes and quality of life.

Related Videos
1 expert in this video
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
4 experts in this video
© 2025 MJH Life Sciences

All rights reserved.